Abound Wealth Management’s Invesco S&P MidCap Momentum ETF XMMO Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q2
$21.9K Sell
129
-86
-40% -$14K ﹤0.01% 356
2026
Q1
$31.1K Buy
215
+156
+264% +$22.6K 0.01% 321
2025
Q4
$8.13K Hold
59
﹤0.01% 546
2025
Q3
$7.94K Hold
59
﹤0.01% 538
2025
Q2
$7.55K Hold
59
﹤0.01% 492
2025
Q1
$6.66K Buy
59
+1
+2% +$123 ﹤0.01% 477
2024
Q4
$7.21K Hold
58
﹤0.01% 457
2024
Q3
$7.02K Hold
58
﹤0.01% 476
2024
Q2
$6.64K Hold
58
﹤0.01% 445
2024
Q1
$6.69K Hold
58
﹤0.01% 451
2023
Q4
$5.23K Hold
58
﹤0.01% 494
2023
Q3
$4.68K Hold
58
﹤0.01% 476
2023
Q2
$4.61K Hold
58
﹤0.01% 505
2023
Q1
$4.37K Hold
58
﹤0.01% 443
2022
Q4
$4.34K Buy
58
+1
+2% +$77 ﹤0.01% 375
2022
Q3
$4.01K Buy
+57
New +$4.36K ﹤0.01% 390

Other funds holding XMMO

Abound Wealth Management's XMMO Position: Q2 2026 in Review

Abound Wealth Management reduced its Invesco S&P MidCap Momentum ETF (XMMO) stake by 40% in Q2 2026, selling an estimated $14K and leaving 129 shares worth $21.9K. The position accounts for ﹤0.01% of the portfolio, ranked #356.

Abound Wealth Management first reported a position in XMMO in Q3 2022 and has held it in 16 quarters since. The position peaked at $31.1K in Q1 2026. 482 funds tracked by Wall St. Rank hold XMMO as of Q2 2026.

  • Abound Wealth Management held 129 shares of Invesco S&P MidCap Momentum ETF worth $21.9K as of Q2 2026.
  • Abound Wealth Management sold 86 Invesco S&P MidCap Momentum ETF shares in Q2 2026, an estimated $14K.
  • Invesco S&P MidCap Momentum ETF made up ﹤0.01% of Abound Wealth Management's portfolio in Q2 2026, its #356 holding.
  • Abound Wealth Management first reported a position in Invesco S&P MidCap Momentum ETF in Q3 2022 and has held it in 16 quarters since.
  • Abound Wealth Management's Invesco S&P MidCap Momentum ETF position peaked at $31.1K in Q1 2026.
  • 482 funds tracked by Wall St. Rank held Invesco S&P MidCap Momentum ETF as of Q2 2026.

Based on Abound Wealth Management's 13F filing for Q2 2026, filed 10 Jul 2026.